



ANDA 090384

**ANDA APPROVAL**

Fresenius Kabi USA, LLC  
Three Corporate Drive  
Lake Zurich, IL 60047  
Attention: Dimitar Ivanov  
Regulatory Technical Manager

Dear Dimitar Ivanov:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on February 4, 2008, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Pemetrexed for Injection USP, 100 mg/vial, 500 mg/vial, 750 mg/vial, and 1 gram/vial Single-Dose Vials.

Reference is also made to the tentative approval letter issued by this office on May 1, 2020, and to any amendments thereafter.

Reference is also made to the ANDA Suitability Petition (FDA-2012-P-1259) submitted on December 21, 2012, under Section 505(j)(2)(C) of the FD&C Act and approved on September 23, 2016. This petition requested the Agency make a determination as to whether an application for Pemetrexed for Injection USP, 750 mg/vial Single-Dose Vial, was suitable for submission as an ANDA. This determination was necessary because the strength proposed in your ANDA differs from the strength of the reference listed drug (RLD), Alimta for Injection, 500 mg/vial of Eli Lilly and Company (Lilly).

Reference is also made to the ANDA Suitability Petition (FDA-2011-P-0052) submitted on January 19, 2011, under Section 505(j)(2)(C) of the FD&C Act and approved on March 29, 2012. This petition requested the Agency make a determination as to whether an application for Pemetrexed for Injection USP, 1 gram/vial Single-Dose Vial, was suitable for submission as an ANDA. This determination was necessary because the strength proposed in your ANDA differs from the strength of the reference listed drug (RLD), Alimta for Injection, 500 mg/vial of Lilly.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly, the ANDA is **approved**, effective on the date of this letter. We have determined your Pemetrexed for Injection USP, 100 mg/vial and 500 mg/vial Single-Dose Vials, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Alimta for Injection, 100 mg/vial and 500 mg/vial of Lilly. Your Pemetrexed for Injection USP, 750 mg/vial and 1 gram/vial Single-Dose Vials can

be expected to have the same therapeutic effect as that of the listed drug product upon which the agency relied as the basis of safety and effectiveness.

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

## **REPORTING REQUIREMENTS**

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98 and at section 506I of the FD&C Act. The Agency should be advised of any change in the marketing status of this drug or if this drug will not be available for sale after approval. In particular, under section 506I(b) of the FD&C Act, you are required to notify the Agency in writing within 180 days from the date of this letter if this drug will not be available for sale within 180 days from the date of approval. As part of such written notification, you must include (1) the identity of the drug by established name and proprietary name (if any); (2) the ANDA number; (3) the strength of the drug; (4) the date on which the drug will be available for sale, if known; and (5) the reason for not marketing the drug after approval.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling materials prior to publication or dissemination. Please note that these submissions are voluntary. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert (PI), Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <https://www.fda.gov/media/128163/download>).

You must also submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <https://www.fda.gov/media/73013/download>. Information and Instructions for completing the form can be found at <https://www.fda.gov/media/132152/download>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/opdp-ectd>.

## **ANNUAL FACILITY FEES**

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions<sup>1</sup> with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee.

Self-identification must occur by June 1<sup>st</sup> of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the *Federal Register* notice announcing facility fee amounts.

All finished dosage forms or active pharmaceutical ingredients manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <https://www.fda.gov/media/71211/download>. The SPL will be accessible via publicly available labeling repositories.

We remind you that you must continually monitor available labeling resources such as DRUGS@FDA for changes to your reference listed drug's labels and labeling and make any necessary revisions to your labels and labeling. More information on post-approval labeling changes may be found in the guidance for industry titled "Changes to an Approved NDA or ANDA" at <https://www.fda.gov/media/71846/download>.

Sincerely yours,

*{See appended electronic signature page}*

For Edward M. Sherwood  
Director  
Office of Regulatory Operations  
Office of Generic Drugs  
Center for Drug Evaluation and Research

---

<sup>1</sup> Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III).



John  
Ibrahim

Digitally signed by John Ibrahim

Date: 5/25/2022 08:47:43AM

GUID: 542af06d0124375c12e8c1d9fc86e87c